Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials

Vermeire, Séverine; E. Sands, Bruce; Peyrin‐Biroulet, Laurent; D’Haens, Geert; Panés, Julián; Yarur, Andrés; C. Wolf, Douglas; E. Ritter, Timothy; Schreiber, Stefan; Woolcott, John; Modesto, Irene; J. Keating, Michael; Shan, Kevin; Wu, Joseph; Chiorean, Michael; Baert, Filip; C. Dubinsky, Marla; Goetsch, Martina; Danese, Silvio; G. Feagan, Brian

doi:10.1093/ecco-jcc/jjae079

Public

Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials

Published in Journal of Crohn s and Colitis • Jun 15, 2024

Authors:

Séverine Vermeire

Bruce E. Sands

Laurent Peyrin‐Biroulet

Abstract

BACKGROUND AND AIMS: Etrasimod is an oral, once daily, selective, sphingosine 1-phosphate [S1P]1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis [UC]. This subgroup analysis evaluated the efficacy and safety of etrasimod 2 mg once daily vs placebo by prio...

View

Open Access

Subject

Medicine

Placebo

Internal medicine

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!